真实世界人群中RAAS抑制剂相关高钾血症风险及治疗中断相关因素
CKD分期进展与治疗中断和终止风险增加相关,严重高钾血症与终止风险显著相关。预防高钾血症可能减少不必要的治疗中断。
要点
- RAAS抑制剂使用者高钾血症发生率为1.30/100患者年。
- CKD 4-5期患者治疗中断和终止风险显著增加。
- 严重高钾血症与治疗终止风险显著相关(HR 3.37)。
核心结论
- RAAS抑制剂治疗中断和终止风险随CKD分期进展而增加。
- 针对中断原因(尤其是终止)如预防高钾血症的措施,可能减少本可获益患者(如CKD、心衰或糖尿病)的治疗空白期。
主要发现
- 高钾血症(血清K+>5.5 mmol/L)发生率为1.30(95%CI 1.28-1.32)/100患者年。
- 73.7%的患者经历治疗空白期,其中57.6%仅中断,7.5%仅终止,8.6%两者均有。
- 开始RAAS抑制剂治疗1年内,约三分之一患者经历中断或终止。
- 严重高钾血症患者中断的HR为1.10(95%CI 10.5-1.16),终止的HR为3.37(95%CI 3.25-3.50)。
- 与无CKD相比,CKD 4期和5期中断风险HR分别为1.20(95%CI 1.16-1.25)和1.57(95%CI 1.44-1.72),终止风险HR分别为2.20(95%CI 2.07-2.33)和2.87(95%CI 2.56-3.22)。
临床怎么用
- 对CKD、心衰或糖尿病患者使用RAAS抑制剂时,应监测血钾以预防高钾血症,减少不必要的治疗中断。
- CKD 4-5期患者使用RAAS抑制剂时中断和终止风险更高,需加强随访管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperkalemia rates in renin-angiotensin-aldosterone system (RAAS) inhibitor users, and factors associated with treatment interruptions and cessations, have not been explored in a large, population-wide database. METHODS: RAAS inhibitor users were identified in the linked UK Clinical Practice Research Datalink-Hospital Episodes Statistics data set, 2009-15. Treatment interruptions (no active prescription followed by reappearance) and cessations were determined. Hyperkalemia (serum K+>5.5 mmol/L) rates were calculated and factors associated with interruptions and cessations modeled using time-varying Cox regression, including hyperkalemia (as a time-dependent variable). RESULTS: Among 434 027 RAAS inhibitor users, the hyperkalemia rate was 1.30 (95% confidence interval 1.28-1.32) per 100 patient-years. Of 73.7% of patients who experienced off-treatment periods, 57.6% experienced interruption only, 7.5% cessation only and 8.6% both. Within 1 year of initiating RAAS inhibitor treatment, approximately one-third of the patients experienced interruption or cessation. Hazard ratios for patients with severe hyperkalemia were 1.10 (10.5-1.16) for interruptions and 3.37 (3.25-3.50) for cessation. Compared with no chronic kidney disease (CKD), risk of interruption was 1.20 (1.16-1.25) and 1.57 (1.44-1.72) for Stages 4 and 5, respectively, and of cessation was 2.20 (2.07-2.33) and 2.87 (2.56-3.22). Risk of interruption increased for patients with heart failure or diabetes [1.04 (1.02-1.05); 1.13 (1.12-1.14), respectively] but the risk of cessation decreased [0.85 (0.82-0.87); 0.92 (0.90-0.94)]. CONCLUSIONS: Risk of RAAS inhibitor interruption and cessation increased as CKD stage progressed. Efforts targeting reasons for interruptions and, especially, cessations, such as hyperkalemia prevention, could decrease off-treatment periods for patients who would otherwise benefit, such as those with CKD, heart failure or diabetes.
引用
- Wetmore JB, Yan H, Horne L, et al. Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. Nephrol Dial Transplant. 2021. PMID: 31846025. doi:10.1093/ndt/gfz263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。